Sign in
Not yet taking people in United StatesNo phase

Inhaled Nitric Oxide Gas Tested in Adults With Severe Obesity and Breathing Failure

Tests inhaled nitric oxide gas in severely obese adults with low blood oxygen.

Key facts

Who runs it
Massachusetts General Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
Inhaled Nitric Oxide in Severe Obesity
Status
Not yet recruiting
People taking part
60 people, planned
Started
Oct 2026
Expected to end
Dec 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Nitric oxide
Record updated
20 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in an intensive care unit who are on a breathing machine. Most have sudden low blood oxygen. Some are controls without it. It studies inhaled nitric oxide in people with severe obesity and normal body weight.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Sudden low blood oxygen (PaO2/FiO2 ≤ 300 mmHg or SpO2/FiO2 ≤ 315) and on a breathing machine for less than 72 hours. Controls are on a breathing machine without sudden low blood oxygen. All are in a participating MGH ICU.
Earlier treatment
No inhaled or oral lung blood-vessel-widening medicine in the 24 hours before joining.
Biomarker or test result
Blood oxygen levels as listed under disease stage. Baseline methemoglobin must be below 3%. Having a known G6PD deficiency excludes people.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Chronic low oxygen needing home oxygen or a home breathing machine
  • Collapsed lung or sudden blood clot in the lung
  • Unstable blood pressure or heart pumping function under 20%
  • Past lung removal or lung transplant

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Acute hypoxemic respiratory failure, defined as persistent hypoxemia (PaO2/FiO2 ≤ 300 mmHg or SpO2/FiO2 ≤ 315) and on invasive mechanical ventilation for < 72 hours
  • Presence of an arterial and central venous catheter (for blood gas measurement)
  • Admitted to a participating MGH ICU
  • Receiving invasive mechanical ventilation and do not have a diagnosis of acute hypoxemic respiratory failure (PaO2/FiO2 > 300 mmHg or SpO2/FiO2> 315)
  • Presence of an arterial catheter
  • Admitted to a participating MGH ICU

Who cannot take part

  • Use of inhaled or oral pulmonary vasodilatory therapy within the 24 hours preceding study enrollment
  • Hemodynamic instability at the time of potential study enrollment defined as:; Persistent systolic blood pressure < 90 mmHg or >180 mmHg despite the use of vasopressor or vasodilators or; Requiring an increment in inotropic-vasopressors over the past two hours just before enrollment: more than 15 mcg/min for norepinephrine and dopamine, more than 10 mcg/min in epinephrine; and more than 50 mcg/ min for phenylephrine; EIT assessments of lung perfusion will only be performed in participants who are already receiving neuromuscular blocking agents (e.g., cisatracurium) at the time of study enrollment. EIT assessments of lung perfusion will not be performed in participants who have the following contraindications to EIT perfusion monitoring:
  • Chronic pulmonary vascular disease on home chemical vasodilator support (e.g., sildenafil)
  • History of lung resection or transplant
  • Usage of any devices with electric current generation such as pacemaker or internal cardiac defibrillator; For controls without acute hypoxemic respiratory failure
  • Contraindication to inhaled NO; Baseline Methemoglobin ≥ 3%; Known left ventricle ejection fraction < 20%; Known history of G6PD deficiency or cytochrome issues; Prior adverse reaction to inhaled nitric oxide
  • Hypernatremia (serum sodium > 150 mEq/L)
  • Age < 18 years
  • Age < 18 years
  • Pregnancy or known active breastfeeding
  • Prisoner or Incarceration
  • Inability or unwillingness of subject or legal surrogate/representative to give written informed consent
  • Presence of pneumothorax or acute pulmonary embolism
  • Chronic hypoxemia requiring home supplemental non-invasive oxygen (nasal cannula or positive pressure ventilation) or home mechanical ventilation
  • Pregnancy or known active breastfeeding
  • Prisoner or Incarceration
  • Inability or unwillingness of subject or legal surrogate/representative to give written informed consent

Other criteria

  • For participants with acute hypoxemic respiratory failure

Where in United States

  • Massachusetts General HospitalBoston, United StatesContact: Timothy Gaulton, MD, MscNot yet recruiting

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn about the effects of inhaled nitric oxide on oxygenation and lung perfusion in participants with severe obesity who have acute hypoxemic respiratory failure and are on mechanical ventilation

Read full original descriptionShow less

The main questions it aims to answer are:

1. In acute hypoxemic respiratory failure, what are the effects of inhaled nitric oxide on oxygenation in participants with severe obesity compared to participants with normal body weight. 2. In acute hypoxemic respiratory failure, what are the effects of inhaled nitric oxide on lung perfusion and heart function in participants with severe obesity compared to participants with normal body weight. 3. In acute hypoxemic respiratory failure, does severe obesity impact nitric oxide signaling pathways?

Participants with acute hypoxemic respiratory failure will be exposed to inhaled nitric oxide (20 ppm) while being clinically monitored.

The 2 groups in the trial

  • Acute hypoxemic respiratory failureTreatment being tested

    Participants (n = 40) with acute hypoxemic respiratory failure will receive inhaled nitric oxide (20 ppm) for 15 min.

    Treatment: Nitric oxide

  • Participants without acute hypoxemic respiratory failureNo study treatment, for comparison

    Participants (n = 20) without acute hypoxemic respiratory failure will not receive inhaled nitric oxide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect of Inhaled Nitric Oxide on Intrapulmonary Shunt in Acutely Hypoxemic Patients With Severe Obesity
Plain-language title
Inhaled Nitric Oxide Gas Tested in Adults With Severe Obesity and Breathing FailureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
20 May 2026